NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 1 percent year over year, thanks largely to a 6 percent increase in pharmaceutical and clinical service revenues, which offset flat molecular diagnostic testing revenues.

For the three months ended June 30, the firm reported total revenues of $200.9 million, up from $199.6 million in fiscal Q4 2017, and beating the consensus Wall Street estimate of $195.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.